Johnson & Johnson and AbbVie Report Q1 Earnings with Divergent Performance
Johnson & Johnson reported strong revenue growth driven by oncology products, while AbbVie saw robust performance in immunology despite a decline from Humira. Both companies posted solid results but took different strategic paths.
Topics: dividend increase earnings report pharmaceuticals pipeline charge